- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02567188
A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis
14 januari 2016 uppdaterad av: Hoffmann-La Roche
An observational, longitudinal, multi-center, non-interventional study in participants with chronic kidney disease (CKD) stage 3-4, assessed by Modification of Diet in Renal Disease (MDRD) to collect data regarding safety and efficacy in participants with pre-dialysis situation who are treated with MIRCERA in normal clinical environment.
Studieöversikt
Studietyp
Observationell
Inskrivning (Faktisk)
144
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Angeholm, Sverige, S-262 81
-
Bollnas, Sverige, 821 81
-
Eskilstuna, Sverige, 63188
-
Gaevle, Sverige, 80187
-
Goeteborg, Sverige, 41345
-
Gothenburg, Sverige, S-402 76
-
Huddinge, Sverige, 14186
-
Jonkoping, Sverige, 55185
-
Karlshamn, Sverige, S-374 80
-
Karlstad, Sverige, 65185
-
Kristianstad, Sverige, 29185
-
Linkoeping, Sverige, S-581 85
-
Mölndal, Sverige, S-431 80
-
Norrkoeping, Sverige, 60182
-
Skövde, Sverige, 54185
-
Stockholm, Sverige, 17176
-
Stockholm, Sverige, 18288
-
Umea, Sverige, 90185
-
Värnamo, Sverige, 33185
-
Västervik, Sverige, 59381
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Icke-sannolikhetsprov
Studera befolkning
Adult participants with CKD Stage 3-4 treated with MIRCERA
Beskrivning
Inclusion Criteria:
- Adult participants above 18 years of age
- Pre-dialysis participants with CKD stage 3-4 treated with MIRCERA and continue in the pre-dialysis state for the whole study period
- Estimated glomerular filteration rate (e-GFR) between 15-60 milliliter per minute (mL/min) (calculated)
Exclusion Criteria:
- Participants involved in interventional trials
- Participants with life expectancy less than 1 year
- Active malignancy
- Planned living kidney transplant within 6 months.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Cohort of CKD Participants
Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Reaching a Hemoglobin (Hb) Value of Greater Than (>) 100 and Less Than (<) 120 Grams Per Liter (gm/L) at Month 6 Before Inclusion
Tidsram: Pre-baseline (Month -6)
|
Pre-baseline (Month -6)
|
|
Percentage of Participants Reaching a Hb Value of >100 and < 120 gm/L at Month 3 Before Inclusion
Tidsram: Pre-baseline (Month -3)
|
Pre-baseline (Month -3)
|
|
Percentage of Participants Reaching a Hb Value of >100 and < 120 gm/L at Baseline
Tidsram: Baseline
|
Baseline
|
|
Percentage of Participants Reaching a Hb Value of > 100 and < 120 gm/L at Month 3 After Inclusion
Tidsram: Month 3
|
Month 3
|
|
Percentage of Participants Reaching a Hb Value of > 100 and < 120 gm/L at Month 6 After Inclusion
Tidsram: Month 6
|
Month 6
|
|
Percentage of Participants Reaching a Hb Value of > 100 and < 120 gm/L at Month 9 After Inclusion
Tidsram: Month 9
|
Month 9
|
|
Percentage of Participants Reaching a Hb Value of > 100 and < 120 gm/L at Month 12 After Inclusion
Tidsram: Month 12
|
Month 12
|
|
Mean Hb Value at Month 6 Before Inclusion
Tidsram: Pre-baseline (Month -6)
|
Pre-baseline (Month -6)
|
|
Mean Hb Value at Month 3 Before Inclusion
Tidsram: Pre-baseline (Month -3)
|
Pre-baseline (Month -3)
|
|
Mean Hb Value at Baseline
Tidsram: Baseline
|
Baseline
|
|
Mean Hb Value at Month 3 After Inclusion
Tidsram: Month 3
|
Month 3
|
|
Mean Hb Value at Month 6 After Inclusion
Tidsram: Month 6
|
Month 6
|
|
Mean Hb Value at Month 9 After Inclusion
Tidsram: Month 9
|
Month 9
|
|
Mean Hb Value at Month 12 After Inclusion
Tidsram: Month 12
|
Month 12
|
|
Percentage of Participants With Hb Fluctuation From Pre-Baseline (Month -6) to Baseline
Tidsram: Pre-baseline (Month -6) to Baseline
|
Hb fluctuation was defined as change in Hb value >15 gm/L between 2 visits.
|
Pre-baseline (Month -6) to Baseline
|
Percentage of Participants With Hb Fluctuation From Baseline to Month 12
Tidsram: Baseline to Month 12
|
Hb fluctuation was defined as change in Hb value >15 gm/L between 2 visits.
|
Baseline to Month 12
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With Change in MIRCERA Treatment
Tidsram: Months 3, 6, 9, and 12
|
Change in MIRCERA treatment included changes in dose, frequency, and route of administration.
|
Months 3, 6, 9, and 12
|
Percentage of Participants With Number of MIRCERA Dose Changes
Tidsram: Baseline to Month 12
|
Baseline to Month 12
|
|
Correlation of Hb Levels With Underlying Disease
Tidsram: Baseline to 12 months
|
Baseline to 12 months
|
|
Correlation of Hb Levels With Levels of Inflammation
Tidsram: Baseline to 12 months
|
Baseline to 12 months
|
|
Percentage of Participants With Changes in Iron Supplement
Tidsram: Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Percentage of participants who had any change in their iron supplement medication at a specified visit were reported.
|
Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Percentage of Participants With Changes in Immunosuppressive Treatment
Tidsram: Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Percentage of participants who had any change in their immunosuppressive medication at a specified visit were reported.
|
Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Percentage of Participants With Changes in AntihypertensiveTreatment
Tidsram: Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Percentage of participants who had any change in their antihypertensive medication at a specified visit were reported.
|
Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Number of Participants With Different Medication Treatment
Tidsram: Pre-baseline (Month -6) to Month 12
|
Number of participants who were receiving different treatments (antihypertensive, immunosuppressive, iron supplements, and others) before and/or after baseline were reported.
Same participant could be reported in more than one category.
|
Pre-baseline (Month -6) to Month 12
|
Percentage of Participants Who Required Blood Transfusion
Tidsram: Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
Pre-baseline (Months -6 and -3), baseline, Months 3, 6, 9 and 12
|
|
Percentage of Participants Who Required Renal Replacement Therapy
Tidsram: Months 3, 6, 9, and 12
|
Renal replacement therapy was defined as hemodialysis and peritoneal dialysis.
|
Months 3, 6, 9, and 12
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 april 2009
Primärt slutförande (Faktisk)
1 april 2011
Avslutad studie (Faktisk)
1 april 2011
Studieregistreringsdatum
Först inskickad
28 september 2015
Först inskickad som uppfyllde QC-kriterierna
30 september 2015
Första postat (Uppskatta)
2 oktober 2015
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
15 februari 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 januari 2016
Senast verifierad
1 januari 2016
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- ML22439
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Anemi
-
Assistance Publique - Hôpitaux de ParisHar inte rekryterat ännuSvår aplastisk anemi | Idiopatisk aplastisk anemi | Måttlig aplastisk anemi som kräver transfusioner
-
University of UtahNovartisAvslutadSvår aplastisk anemi | Måttlig aplastisk anemi | Mycket svår aplastisk anemiFörenta staterna
-
National Heart, Lung, and Blood Institute (NHLBI)AvslutadAnemi, aplastisk | Anemi, hypoplastiskFörenta staterna
-
Hospital Universitario Dr. Jose E. GonzalezAvslutadPerniciös anemi | Megaloblastisk anemi nrMexiko
-
Peking University People's HospitalRekrytering
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes... och andra samarbetspartnersRekrytering
-
Federal Research Institute of Pediatric Hematology...Rekrytering
-
Jiangsu HengRui Medicine Co., Ltd.Avslutad
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School... och andra samarbetspartnersAvslutad
-
Jiangsu HengRui Medicine Co., Ltd.Avslutad